General Cancer News
Top Stories
Integrating Genetic Information With Breast Cancer Risk Factors May Help Refine Prognosis
POSTED: April 15, 2008Incorporating genetic information known as gene expression signatures with clinical and other risk factors for breast cancer may help refine estimates of relapse-free survival and predicted response to chemotherapy, according to a study in the April 2 issue of JAMA. "The advent of genomic technology for the analysis of human tumor samples has now added ...
Pilot Study To Evaluate Sir-Spheres In Combination With Bevacizumab And Chemotherapy As First Line Treatment For Metastatic Colorectal Cancer
POSTED: April 15, 2008WILMINGTON, Mass. -- Sirtex, a leading developer of targeted and innovative cancer therapies, has received FDA approval under Investigational Device Exemption to conduct the first clinical trial to evaluate the safety of concurrent administration of FOLFOX6 and bevacizumab, an anti-angiogenic, with Selective Internal Radiation Therapy (SIRT) usi...
Superior Lymph Node Resection Is Achievable With Laparoscopic Colectomy: Even In Initial 30 Cases
POSTED: April 15, 2008The adequacy of laparoscopic-assisted colectomy (LAC) for colon cancer has been heavily scrutinized, causing most surgeons to await survival data before undertaking laparoscopic resection for malignancy. However, encouraging results published by Lacy et al. in 2002(1) included experienced laparoscopic surgeons in a randomized trial comparing LAC agai...
Researchers Find Non-Toxic Agents Added To Conventional Chemotherapy Decrease Survival Of Colon Cancer Cells
POSTED: April 15, 2008SAN DIEGO -- Researchers from the Barbara Ann Karmanos Cancer Institute in Detroit today presented findings showing that adding curcumin or resveratrol to conventional chemotherapy could be effective in preventing the growth of chemo-resistant colon cancer cells. The poster presentation was delivered at the American Association for Cancer Rese...
BSI-201 Demonstrates Significant Tumor Growth Inhibition And Increased Survival Rates In Preclinical Ovarian Cancer Studies
POSTED: April 15, 2008SAN DIEGO -- BiPar Sciences, Inc. today announced positive preclinical data demonstrating the activity of its lead poly ADP-ribose polymerase (PARP) inhibitor, BSI-201, in ovarian cancer models. The results highlight the anti-tumor activity of BSI-201 through PARP activity inhibition, tumor growth suppression, and extended survival in multi-drug...
Pill Use Is Associated With Reductions In Overall Risk Of Cancer And In Risk of Main Gynecologic Cancers
POSTED: April 15, 2008Ever-use of the pill had no adverse effect on the overall risk of cancer in the large cohort of British women participating in the Royal College of General Practitioners' oral contraception study. Rather, analyses of data reflecting as much as 36 years of observation indicate that ever-users of oral contraceptives had a 12% reduction in the risk of ...
HiFi DNA Tech Tells FDA It Is Unreasonable And Should Study The Science Of HPV DNA PCR And DNA Sequencing For Genotyping
POSTED: April 15, 2008BRIDGEPORT, Conn. -- HiFi DNA Tech of Trumbull, CT told a federal judge the Food and Drug Administration (FDA) "has not kept pace with the advances in molecular biology for the past 20 years, which unfortunately does not benefit women who may have HPV." The Memorandum in Opposition was filed in U.S. District Court in Bridgeport, CT, April 11 in ...
Celebrex-Lipitor Combination May Halt Prostate Cancer
POSTED: April 15, 2008WASHINGTON -- Administering a combination of the widely used drugs Celebrex, an anti-inflammatory drug, and Lipitor, a cholesterol-lowering drug, stops the transition of early prostate cancer to its more aggressive and potentially fatal stage, according to a new study released by U.S. researchers. The findings were presented at the annual mee...
Life Beyond the Chemotherapy: Hospitals Offer Cancer Survivors Help to Regain Their Fitness
POSTED: April 15, 2008For decades, oncologists have focused on ways to help patients survive cancer. What they didn't pay much attention to was what happened when people did. That thinking has begun to change in recent years with advancements in treatment and an increase in the number of survivors. A growing number of hospitals are turning to fitness to comb...
AVEO Pharmaceuticals' Novel Triple VEGF Receptor Inhibitor Shows Tumor Regression In Patients With Advanced Renal Cancer
POSTED: April 15, 2008SAN DIEGO & CAMBRIDGE, Mass. -- AVEO Pharmaceuticals, Inc., a biotechnology company leveraging breakthrough discoveries in cancer biology to discover, develop and commercialize targeted oncology therapies, today announced that their novel oral triple VEGF receptor inhibitor AV-951 shows clinical activity in multiple advanced solid tumor types ...
